Lipocine Inc. Reports 89% Revenue Decline in Q3 2025, Net Loss of $3.2 Million

Lipocine Inc. reported its financial results for the third quarter of 2025, revealing a significant decline in revenue compared to the same period in 2024. The company generated total revenues of $114,574 for the three months ended September 30, 2025, compared to no revenue in the same quarter of the previous year. For the nine months ended September 30, 2025, revenues totaled $831,287, a decrease of approximately 89% from $7.7 million in the prior year. The decline was primarily attributed to a drop in licensing revenue, which fell from $7.5 million in 2024 to $500,000 in 2025, while royalty revenue increased from $206,738 to $331,287 during the same period.

Operating expenses for the third quarter increased to $3.5 million, up from $2.6 million in the prior year, driven mainly by higher research and development costs associated with ongoing clinical trials, particularly for LPCN 1154. General and administrative expenses decreased to $767,837 from $1.05 million, reflecting cost-cutting measures. The net loss attributable to common shareholders for the quarter was $3.2 million, or $(0.59) per share, compared to a loss of $2.2 million, or $(0.41) per share, in the same quarter of 2024.

In terms of strategic developments, Lipocine has made significant progress in its licensing agreements. The company entered into multiple agreements, including the Verity License Agreement, which grants exclusive rights to commercialize its TLANDO product in the U.S. and Canada. The agreement includes potential milestone payments of up to $259 million and tiered royalties ranging from 12% to 18% of net sales. Additionally, Lipocine has secured licensing agreements with SPC for South Korea, Pharmalink for the Gulf Cooperation Council, and Aché for Brazil, further expanding its geographic reach.

Operationally, Lipocine's cash and cash equivalents stood at $3.9 million as of September 30, 2025, down from $6.2 million at the end of 2024. The company reported cash used in operating activities of $6.8 million for the nine months ended September 30, 2025, compared to $2.9 million in the same period of 2024. The decrease in cash reserves raises concerns about the company's liquidity, as it anticipates needing additional capital to support ongoing clinical trials and operational needs. Lipocine indicated that it believes its existing capital resources will be sufficient to meet its projected operating requirements through at least November 6, 2026, but it may need to raise additional capital through equity or debt markets or out-licensing activities.

Looking ahead, Lipocine remains focused on advancing its clinical pipeline, particularly LPCN 1154 for postpartum depression and LPCN 2101 for epilepsy. The company is also exploring partnerships for its pipeline assets to facilitate further development and commercialization. However, the ability to achieve these goals is contingent on securing additional funding and successfully navigating the regulatory landscape.